ESMO 2024: Focus on GI Oncology
ESMO 2024: Focus on GI Oncology
Advertisement
Benjamin Weinberg, MD, FACPBile Duct Cancer | March 13, 2025
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
View More
Lorenza Rimassa, MDUnresectable HCC | October 4, 2024
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
Wungki Park, MD, MSESMO 2024: Focus on GI Oncology | September 27, 2024
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Wungki Park, MD, MSESMO 2024: Focus on GI Oncology | September 27, 2024
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
Brandon TwyfordGI Cancer | September 19, 2024
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
Brandon TwyfordColorectal Cancer | September 19, 2024
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
Jordana JampelPancreatic Cancer | September 19, 2024
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
Trevor Leong, MDGastric Cancer | March 13, 2025
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
Jordana JampelPancreatic Cancer | September 17, 2024
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
Jordana JampelGastroesophageal Cancer | September 17, 2024
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
Brandon TwyfordGI Cancer | December 7, 2024
The LEAP-012 study showed improved progression-free survival with lenvatinib, pembrolizumab, and TACE in HCC.
Zachary BessetteGastric Cancer | September 17, 2024
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Zev Wainberg, MD, MScGastric Cancer | March 13, 2025
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Josep M. Llovet, MDGI Cancer | March 13, 2025
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
Yelena Janjigian, MDGastric Cancer | March 13, 2025
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Brandon TwyfordColorectal Cancer | September 16, 2024
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Brandon TwyfordGastric Cancer | September 16, 2024
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
Zachary BessetteGEP-NETs | September 13, 2024
Cabozantinib continues to demonstrate significant improvement in PFS in extra-pancreatic or pancreatic neuroendocrine tumors.
Zachary BessetteColorectal Cancer | September 13, 2024
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
Jordana JampelColorectal Cancer | September 12, 2024
Neoadjuvant nivolumab plus relatlimab led to a pathologic response rate of 96%.
Advertisement
Advertisement
Latest News

April 22, 2025